



March 3, 2016

## **Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016**

TUSTIN, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.

To listen to the live webcast, or access the archived webcast, please visit: <http://ir.peregrineinc.com/events.cfm>.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.

### **About Peregrine Pharmaceuticals, Inc.**

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics to stimulate the body's immune system to fight cancer. The company is focused on evaluating its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers. One specific component of this I-O combination strategy includes planned clinical trials of bavituximab in combination with durvalumab, AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, in a range of cancer types under a clinical collaboration.

In addition to its drug development programs, Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit [www.peregrineinc.com](http://www.peregrineinc.com).

Contacts:

Jay Carlson

Peregrine Pharmaceuticals, Inc.

(800) 987-8256

[info@peregrineinc.com](mailto:info@peregrineinc.com)

Stephanie Diaz (Investors)

Vida Strategic Partners

415-675-7401

[sdiaz@vidasp.com](mailto:sdiaz@vidasp.com)

Tim Brons (Media)

Vida Strategic Partners

415-675-7402

[tbrons@vidasp.com](mailto:tbrons@vidasp.com)

 Primary Logo

Source: Peregrine Pharmaceuticals Inc.

News Provided by Acquire Media